Masafumi Kawanishi
8PUBLICATIONS
5CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Feb 20, 2026
Impact of anti-drug antibodies and neutralising antibodies on safety and efficacy of ozoralizumab in rheumatoid arthritis.Masafumi Kawanishi, Tsutomu Takeuchi, Nobuko Horiuchi
|Jan 27, 2025
Effect of Ozoralizumab Administration with or without Methotrexate in Patients with Rheumatoid Arthritis: A Post-Hoc Analysis.Yoshiya Tanaka, Nobuko Horiuchi, Cosmo Sasajima
|Nov 01, 2023
Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis.Tsutomu Takeuchi, Yukihiro Chino, Yoko Mano
|Oct 07, 2023
Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis.Tsutomu Takeuchi, Megumi Nakanishi, Masafumi Kawanishi
|Apr 13, 2023
Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials.Tsutomu Takeuchi, Yukihiro Chino, Masafumi Kawanishi
|Oct 06, 2022
Efficacy and safety of anti-TNF multivalent NANOBODY® compound 'ozoralizumab' without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial).Yoshiya Tanaka, Masafumi Kawanishi, Megumi Nakanishi
Pageof 2
